Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.92 |
| ▸ | BCHE | P06276 | 4/20 | 0.92 |
| ▸ | MEN1 | O00255 | 4/20 | 0.92 |
| ▸ | BLM | P54132 | 4/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.92 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.92 |
| ▸ | MAPT | P10636 | 3/20 | 0.92 |
| ▸ | THRB | P10828 | 3/20 | 0.92 |
| ▸ | HPGD | P15428 | 3/20 | 0.92 |
| ▸ | CASP1 | P29466 | 3/20 | 0.92 |
| ▸ | RECQL | P46063 | 3/20 | 0.92 |
| ▸ | CASP7 | P55210 | 3/20 | 0.92 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.92 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.92 |
| ▸ | TERT | O14746 | 3/20 | 0.61 |
| ▸ | MITF | O75030 | 2/20 | 0.61 |
| ▸ | NSD2 | O96028 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30379131 | 0.96 | ACHE (1.00) | ACHEBCHEMEN1BLMKMT2A | |
| SCHEMBL55279 | 0.96 | ACHE (1.00) | ACHEBCHEMEN1BLMKMT2A | |
| Iodide SCHEMBL29527724 | 0.95 | ACHE (1.00) | ACHEBCHEMEN1BLMKMT2A | |
| Hydrochloric Acid SCHEMBL5482694 | 0.95 | ACHE (0.98) | ACHEBCHEMEN1BLMKMT2A | |
| Iodide SCHEMBL29351886 | 0.95 | ACHE (1.00) | ACHEBCHEMEN1BLMKMT2A | |
| SCHEMBL16331307 | 0.95 | ACHE (0.98) | ACHEBCHEMEN1BLMKMT2A | |
| Bromide SCHEMBL30669741 | 0.95 | ACHE (0.98) | ACHEBCHEMEN1BLMKMT2A | |
| Iodide SCHEMBL14996 | 0.95 | ACHE (1.00) | ACHEBCHEMEN1BLMKMT2A | |
| Bromide SCHEMBL290404 | 0.95 | ACHE (0.98) | ACHEBCHEMEN1BLMKMT2A | |
| Water SCHEMBL9106337 | 0.94 | ACHE (0.98) | ACHEBCHEMEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117164663-B | Polypeptide compound, composition and use thereof | 青岛双元泰和药业有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-110531092-B | Cell analysis system, reagent selection support device, reagent selection support method, and storage medium | 希森美康株式会社 | 2024-04-12 | — | — | CN | disclosed |
| CN-117586214-A | Linderane type sesquiterpene dimer and preparation method and application thereof | 中国科学院昆明植物研究所 | 2024-02-23 | — | — | CN | disclosed |
| CN-117164663-A | Polypeptide compound, composition and use thereof | 青岛双元泰和药业有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230212247-A1 | MODIFIED CXCL10 FOR IMMUNOTHERAPY OF CANCER DISEASES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2023-07-06 | — | — | US | disclosed |
| EP-4168431-A1 | MODIFIED CXCL10 FOR IMMUNOTHERAPY OF CANCER DISEASES | Technion Research & Development Foundation Limited (IL) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021260685-A1 | MODIFIED CXCL10 FOR IMMUNOTHERAPY OF CANCER DISEASES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2021-12-30 | — | — | WO | disclosed |
| US-8440615-B2 | Pharmaceutical and/or cosmetic composition containing active-principle activators of aconitase | SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS (VINCIENCE) (FR) | 2013-05-14 | — | — | US | disclosed |
| US-20120263794-A1 | TREATMENT OF EYE DISEASES USING ENCAPSULATED CELLS ENCODING AND SECRETING A NEUROPROTECTIVE FACTOR AND/OR AN ANTI-ANGIOGENIC FACTOR | BIOCOMPATIBLE UK LTD. (GB) | 2012-10-18 | — | — | US | disclosed |
| CN-102438647-A | Treatment of ocular diseases using encapsulated cells encoding and secreting neuroprotective and/or anti-angiogenic factors | BIOCOMPATIBLES UK LTD | 2012-05-02 | — | — | CN | disclosed |
| US-20080021088-A1 | Retinoid Derivatives With Antiangiogenic, Antitumoral And Proapoptotic Activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-01-24 | — | — | US | disclosed |
| US-20040235757-A1 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-11-25 | — | — | US | disclosed |
| US-20040151713-A1 | Cell cycle regulatory factor | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-05 | — | — | US | disclosed |
| EP-1412317-A1 | RETINOID DERIVATIVES WITH ANTIANGIOGENIC, ANTITUMOR AND PROAPOPTOTIC ACTIVITIES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-04-28 | — | — | EP | disclosed |
| EP-1396545-A1 | CELL CYCLE REGULATORY FACTOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-20030078406-A1 | Methods and compositions for DRM, a secreted protein with cell growth inhibiting activity | THE GOVERNMENT OF THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH & HUMAN SERVICES | 2003-04-24 | — | — | US | disclosed |
| WO-2003011808-A1 | RETINOID DERIVATIVES WITH ANTIANGIOGENIC, ANTITUMORAL AND PROAPOPTOTIC ACTIVITIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-02-13 | — | — | WO | disclosed |
| US-20010006783-A1 | METHOD AND APPARATUS FOR DETECTING BACTERIA | ISOLA USA CORP. | 2001-07-05 | — | — | US | disclosed |
| WO-1999049041-A1 | DRM, A SECRETED PROTEIN WITH CELL GROWTH INHIBITING ACTIVITY, AND RELATED METHODS AND COMPOSITIONS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-09-30 | — | — | WO | disclosed |
| EP-0940472-A1 | METHOD AND APPARATUS FOR DETECTING BACTERIA | Organo Corporation (JP) | 1999-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021088-A1 | Retinoid Derivatives With Antiangiogenic, Antitumoral And Proapoptotic Activities | RARA, RARB, RXRA | ACHE 4238/4885BCHE 4251/4885MEN1 3834/4885 |
| US-20040235757-A1 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | RARA, RARB, RARG | ACHE 4338/4885BCHE 4031/4885MEN1 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.